Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 457-470

  Knox, Susan J ^a,c   Goris, Michael L ^a   Trisler, Kirk ^a   Negrin, Robert ^a   Davis, Thomas ^a   Liles, Tina Marie ^a   Grillo López, Antonio ^b   Chinn, Paul ^b   Varns, Chet ^b   Ning, Shou Cheng ^a   Fowler, Sherry ^a   Deb, Nimisha ^a   Becker, Mark ^a   Marquez, Carol ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CD20 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IND BB 3948; INDIUM 111; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ANTIBODY LABELING; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TISSUE DISTRIBUTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; RECURRENCE; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 9044254117     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. DeVita, V. T., Jaffe, E. S., Mauch, P., and Longo, D. L. Lymphocytic lymphomas. In: V T. DeVita, S. Hellman, and S. A. Rosenberg (eds.). Cancer: Principals and Practice of Oncology, pp. 1741-1798. Philadelphia. J. B Lippincott Company, 1989.
2. Maloney, D. G., Liles, T. M., Czerwinski, D. K., Waldichuk, C., Rosenberg, J., Grillo-López, A. J., and Levy, R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84: 2457-2466, 1994.
3. Maloney, D. G., Levy, R., and Miller, R. A. Monoclonal anti-idiotype antibody therapy of lymphoma. In: V. T. DeVita, S. Hellman, and S. A Rosenberg (eds.), Biologic Therapy of Cancer Update, pp. 1-10, Philadelphia J. B. Lippincott Company, 1992
4. Dyer, M J., Hale, G., Hayhoe, F G., and Waldmann, H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood, 73. 1431-1439, 1989.
5. Hale, G., Dyer, M. J., Clark, M R., Phillips, J. M., Marcus, R., Riechmann, L., Winter, G., and Waldmann, H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2: 1394-1399, 1988.
6. Press, O. W., Appelbaum, F., Ledbetter, J. A., Martin, P. J., Zarling, J., Kidd, P., and Thomas, E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 69: 584-591, 1987.
7. Meeker, T. C., Lowder, J., Maloney, D. G., Miller, R. A., Thielemans, K., Warnke, R., and Levy, R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood, 65: 1349-1363, 1985.
8. Miller, R. A., Maloney, D. G., Warnke, R., and Levy, R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med., 306: 517-522, 1982.
9. Knox, S. Radioimmunotherapy of non-Hodgkin's lymphoma. Semin. Radiat. Oncol., 5: 331-341, 1995.
10. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., and Izon, D. O. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
11. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
12. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., and Porter, B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl J. Med., 329: 1219-1224, 1993.
13. Kuzel, T., Rosen, S. T., Zimmer, A. M., Silverstein, E. A., Spies, S., Saletan, S. L., Norvitch, M. E., Birkhofer, M., Shochat, D., LoBuglio, A. F., Meredith, R., Khazaeli, M. B., Polansky, A., Hu, E , Chen, D., Lee, K., and Watkins, K. A Phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother., 8: 3-16, 1993.
14. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj. Radiopharm., 6: 1-11, 1993.
15. 131-I-anti-B1 (anti-CD20) radioimmunotherapy (RIT) for refractory B-cell lymphomas (Abstract). Blood, 82: 332a, 1993.
16. 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In: D. M. Goldenberg (ed), Cancer Therapy with Radiolabeled Antibodies, pp. 217-227. Boca Raton, FL: CRC Press, Inc., 1994.
17. Lewis, J. P., DeNardo, G. L., and DeNardo, S. J. Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma, 14: 115-120, 1995
18. 131I-Lym-1. Cancer Res., 50 (Suppl.): 1014s-1016s, 1990.
19. Kaminski, M. S., Fig, L. M., Zasadny, K R., Koral, K. F., Del Rosario, R. B., Francis, I R., Hanson, C. A., Normolle, D. P., Mudgett, E., and Liu, C. P. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol. 10: 1696-1711, 1992.
20. Czuczman, M. S., Straus, D. J., Divgi, C. R., Graham, M., Garin, C. P., Finn, R., Myers, J., Old, L. J , Larson, S. M., and Scheinberg, D. A. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma J. Clin. Oncol., 11: 2021-2029, 1993.
21. 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res., 50 (Suppl.): 1022s-1028s, 1990.
22. Press, O. W., Eary, J F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., and Krohn, K. A. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol., 7: 1027-1038, 1989.
23. Badger, C. C., Eary, J., and Brown, S. Therapy of lymphoma with I-131-labeled anti-idiotype antibodies (anti-id). Proc. Am. Assoc. Cancer Res., 28: 388, 1987.
24. 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma. Presented at the ASTRO Annual Meeting, October 8-11, 1995, Miami, FL. Int. J. Radiat. Oncol. Biol. Phys., 32 (Suppl. 1): 215, 1995.
25. 90Y-anti-CD20 monoclonal antibody therapy (IDEC-Y2B8) for recurrent B cell lymphoma. J. Immunother., 16: 161, 1994.
26. Press, O. W., Eary, J. F., Appelbaum, F. R., and Bernstein, I. D. Radiolabeled antibody therapy of lymphomas. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 1-13. Philadelphia: J. B Lippincott Company, 1994.
27. Horibe, K., and Nadler, L. M. Human B cell associated antigens defined by monoclonal antibodies. In: E. R. Heise (ed.), Lymphocyte Surface Antigens, New York: American Society for Histocompatibility and Immunogenetics, 1984.
28. Barclay, A. N., Birkeland, M. L., and Brown, M. H. The Leukocyte Antigen Facts Book. New York: Academic Press, Inc., 1993.
29. Simpkin, D. J., and Mackie, T. R. EGS4 Monte Carlo determination of the beta dose kernel in water. Med. Phys. (NY), 17: 179-186, 1990.
30. Prestwich, W. V., Nunes, J., and Kwok, C. S. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J. Nucl. Med., 30: 1036-1046, 1989.
31. Goris, M. L., Knox, S. A., Nielsen, K. R., and Bouillani, O. Organ modeling in the quancitation of planar images for distribution studies. Cancer (Phila.), 73 (Suppl.): 919-922, 1994.
32. Press, O. W., Eary, J. F., Appelbaum, F. R., and Bernstein, I. D. Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 229-237. Boca Raton, FL: CRC Press, Inc., 1995.
33. Bunn, P. J., Carrasquillo, J. A., Keenan, A. M., Schroff, R. W., Foon, K A., Hsu, S. M., Gazdar, A. F., Reynolds, J. C., Perentesis, P., and Larson, S. M. Imaging of T-cell lymphoma by radiolabelled monoclonal antibody (Letter). Lancet, 2: 1219-1221, 1984.
34. Press, O W., Eary, J. F., Appelbaum, F. R., Badger, C. C., and Bernstein, I. D. Radiolabeled antibody therapy of lymphoma. In: B. Dana (ed.), Malignant Lymphomas, Including Hodgkin's Disease: Diagnosis, Management and Special Problems, pp. 127-145. Boston: Kluwer Academic Publishers, 1993.
35. DeNardo, S. J., DeNardo, D. L., O'Grady, L. F., Levy, N. B., Mills, S. L., Macey, J. P., McGahan, J. P., Miller, C. H , and Epstein, A. L. Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody Antibody Immunoconj. Radiopharm., 1: 17-33, 1988.
36. 131I Lym-1 monoclonal antibodies. Int. J. Cancer, 3 (Suppl.): 96-101, 1988.
37. Kaminski, M. S., Fig, L., Zasadny, K., Koral, I., Francis, R., Miller, R., and Wahl, L. Phase I evaluation of 131-I-MB-1 antibody radioimmunotherapy of B-cell lymphoma (Abstract). Blood, 76 (Suppl.): 355a, 1990.
38. Knox, S. J. Overview of studies of experimental radioimmunotherapy. Cancer Res., 55 (Suppl.): 5832s-5836s, 1995.
39. Schlom, J., Milenic, D. E., Roselli, M., Colcher, D., Bird, R., Johnson, S., Hardman, K D., Guadagni, F., and Greiner, J. W. New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma. Int. J. Radiat. Appl. Instrum. Part B, 18: 425-435, 1991.
40. Schlom, J., Molinolo, A., Simpson, J. F., Siler, K., Roselli, M., Hinkle, G., Houchens, D. P., and Colcher, D. Advantage of dose fractionation m monoclonal antibody-targeted radioimmunotherapy. J. Natl. Cancer Inst., 82: 763-771, 1990.
41. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res., 51: 676-681, 1991.
42. 177lutetium-labeled immunoconjugate. Cancer Res., 51: 2889-2896, 1991.
43. Meredith, R. F., Khazaeli, M. B., Liu, T., Plott, G., Wheeler, R. H., Russell, C., Colcher, D., Schlom, J , Shochat, D., and LoBuglio, A. F. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J. Nucl. Med., 33: 1648-1653, 1992.
44. Buchsbaum, D. J. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp 115-140. Boca Raton, FL: CRC Press, Inc., 1995.
45. Wahl, R. L. Experimental radioimmunotherapy. A brief overview. Cancer (Phila.), 73 (Suppl.): 989-992, 1994.
46. Buchsbaum, D. J., Langmuir, V. K., and Wessels, B. W. Experimental radioimmunotherapy. Med. Phys. (NY), 20: 551-567, 1993.
47. Buchsbaum, D. J., and Lawrence, T. S New trends in the use of radioimmunoconjugates for the therapy of cancer. Targeted Diagn. Ther. Ser., 3: 215-255, 1990.
48. Maloney, D. G., Grillo-López, A. J., Bodkin, D., White, C. Foon, K., Schilder, R. J., Neidhart, J., Janakiraman, N., Waldichuk, C , Davis, T , Dallaire, B. K., Royston, I., and Levy, R. IDEC-C2B8 anti-CD20 antibody: results of long term follow-up of relapsed NHL Phase II trial patients. Blood, 86: 54A, 1995.